147 related articles for article (PubMed ID: 35019820)
1. Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer.
Wu L; Wang W; Tian J; Qi C; Cai Z; Yan W; Xuan S; Shang A
Bioengineered; 2022 Jan; 13(1):1942-1951. PubMed ID: 35019820
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma.
Hsu FT; Tsai CL; Chiang IT; Lan KH; Yueh PF; Liang WY; Lin CS; Chao Y; Lan KL
J Cell Mol Med; 2022 Apr; 26(7):1955-1968. PubMed ID: 35174623
[TBL] [Abstract][Full Text] [Related]
3. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
[TBL] [Abstract][Full Text] [Related]
4. S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model.
Suenaga M; Yamada S; Fujii T; Tanaka C; Kanda M; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
J Surg Oncol; 2016 Mar; 113(4):413-9. PubMed ID: 27100026
[TBL] [Abstract][Full Text] [Related]
5. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
Gao M; Zhang D; Jin Q; Jiang C; Wang C; Li J; Peng F; Huang D; Zhang J; Song S
Oncotarget; 2016 Sep; 7(36):58133-58141. PubMed ID: 27531898
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of
Awasthi N; Schwarz MA; Zhang C; Schwarz RE
Mol Cancer Ther; 2018 Nov; 17(11):2353-2364. PubMed ID: 30166402
[TBL] [Abstract][Full Text] [Related]
7. The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer.
Zhao H; Li R; Wang X; Lu X; Hu M; Zhang J; Zhao X; Song X; Liu Y
J Ovarian Res; 2020 Sep; 13(1):113. PubMed ID: 32958014
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes.
Kolyvas E; Rudloff M; Poruchynsky M; Landsman R; Hollevoet K; Venzon D; Alewine C
Oncotarget; 2017 Feb; 8(6):9189-9199. PubMed ID: 27999204
[TBL] [Abstract][Full Text] [Related]
9. The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer.
Zhang CΗ; Awasthi N; Schwarz MA; Schwarz RE
Int J Oncol; 2013 Nov; 43(5):1627-35. PubMed ID: 24042258
[TBL] [Abstract][Full Text] [Related]
10. Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases.
Volk LD; Flister MJ; Chihade D; Desai N; Trieu V; Ran S
Neoplasia; 2011 Apr; 13(4):327-38. PubMed ID: 21472137
[TBL] [Abstract][Full Text] [Related]
11. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
12. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models.
Li JA; Xu XF; Han X; Fang Y; Shi CY; Jin DY; Lou WH
Pancreas; 2016 Mar; 45(3):425-33. PubMed ID: 26495780
[TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.
Volk LD; Flister MJ; Bivens CM; Stutzman A; Desai N; Trieu V; Ran S
Neoplasia; 2008 Jun; 10(6):613-23. PubMed ID: 18516298
[TBL] [Abstract][Full Text] [Related]
14. Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy.
Chatterjee M; Ben-Josef E; Robb R; Vedaie M; Seum S; Thirumoorthy K; Palanichamy K; Harbrecht M; Chakravarti A; Williams TM
Cancer Res; 2017 Nov; 77(21):5925-5937. PubMed ID: 28923854
[TBL] [Abstract][Full Text] [Related]
15. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
Cullis J; Siolas D; Avanzi A; Barui S; Maitra A; Bar-Sagi D
Cancer Immunol Res; 2017 Mar; 5(3):182-190. PubMed ID: 28108630
[TBL] [Abstract][Full Text] [Related]
16. Albumin Paclitaxel Compared with 5-Penfluorouracil, Lobaplatin, and Albumin Paclitaxel Combined with 5-Penfluorouracil in the Treatment of Human Gastric Cancer Cell AGS Line Autophagy and Apoptosis.
Cheng X; Yang F; Wang Y; Nie W; Mahendra Upadhyay A; Zhang M; Wang Q; Yan Z
Can J Gastroenterol Hepatol; 2022; 2022():6015877. PubMed ID: 35719323
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
18. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
[TBL] [Abstract][Full Text] [Related]
19. Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.
Crawford K; Bontrager E; Schwarz MA; Chaturvedi A; Lee DD; Md Sazzad H; von Holzen U; Zhang C; Schwarz RE; Awasthi N
Cancer Biol Ther; 2021 Dec; 22(10-12):619-629. PubMed ID: 34882068
[TBL] [Abstract][Full Text] [Related]
20. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
[Next] [New Search]
